Intellectual Property (IP), Artificial Intelligence (AI), Open Movements (OM)

Issues and developments related to IP, AI, and OM, examined in the IP and tech ethics graduate courses I teach at the University of Pittsburgh School of Computing and Information. My Bloomsbury book "Ethics, Information, and Technology", coming in Summer 2025, includes major chapters on IP, AI, OM, and other emerging technologies (IoT, drones, robots, autonomous vehicles, VR/AR). Kip Currier, PhD, JD

Showing posts with label Merck & Co.. Show all posts

Saturday, March 26, 2016

Reuters; Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute; Reuters, 3/24/16

Reuters; Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute:

"A federal jury on Thursday ordered Gilead Sciences Inc (GILD.O) to pay Merck & Co (MRK.N) $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.
The damages award is far less than the $2 billion Merck had demanded. On Tuesday, the same jury in San Jose, California, upheld the validity of the patents, which lie at the heart of the dispute over Gilead's blockbuster drugs Sovaldi and Harvoni. Together the medicines had more than $20 billion in U.S. sales in 2014 and 2015."